PCVX Stock Catalyst: Vaxcyte Announced Positive Topline Data from OPUS-1 Phase 3 Trial of VAX-31

Oct 5, 2026 · 5:23am ET

The pivotal adult Phase 3 trial results for the 31-valent pneumococcal conjugate vaccine candidate were positive.

Max move

+86.4%

High of day $107.34

Sparker timei

5:23am ET

PCVX · Oct 5, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Vaxcyte, Inc. (Nasdaq: PCVX) announced positive topline data from the OPUS-1, the pivotal adult Phase 3 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate. The trial met its primary immunogenicity endpoints.

The company did not provide specific figures or comparisons in the announcement. Vaxcyte has a free float of 130,561,752 shares and 148,805,278 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time PCVX sparks.

Download Sniper App →

Catch the next PCVX-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →